Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage

Ryo Nagashio, Eri Arai, Hidenori Ojima, Tomoo Kosuge, Yutaka Kondo, Yae Kanai

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

For appropriate surveillance of patients at the precancerous stage for hepatocellular carcinomas (HCCs), carcinogenetic risk estimation is advantageous. The aim of our study was to establish criteria for such estimation based on DNA methylation profiling. The DNA methylation status of 203 CpG sites on 25 bacterial artificial chromosome (BAC) clones, whose DNA methylation status had been proven to discriminate samples of noncancerous liver tissue obtained from patients with HCC (N) from normal liver tissue (C) samples by BAC array-based methylated CpG island amplification, was evaluated quantitatively using pyrosequencing. The 45 CpG sites whose DNA methylation levels differed significantly between C and N in the learning cohort (n = 22) were identified. The criteria combining DNA methylation status for the 30 regions including the 45 CpG sites were able to diagnose N as being at high risk of carcinogenesis with 100% sensitivity and specificity in the learning cohort and 95.6% sensitivity and 100% specificity in the validation (n = 90) cohort. DNA methylation status for the 30 regions in N samples was significantly correlated with the outcome of patients with HCCs, indicating that clinicopathologically valid DNA methylation alterations have already accumulated at the precancerous stage. The DNA methylation status of the 30 regions did not depend on the presence or absence of hepatitis virus infection, or the status of noncancerous liver tissue (chronic hepatitis or cirrhosis). These criteria may be applicable for carcinogenetic risk estimation using liver biopsy specimens obtained from patients who are followed up because of chronic liver diseases.

Original languageEnglish
Pages (from-to)1170-1179
Number of pages10
JournalInternational Journal of Cancer
Volume129
Issue number5
DOIs
Publication statusPublished - 2011 Sep 1
Externally publishedYes

Fingerprint

DNA Methylation
Liver
Bacterial Artificial Chromosomes
Hepatocellular Carcinoma
Learning
Sensitivity and Specificity
Hepatitis Viruses
CpG Islands
DNA Fingerprinting
Virus Diseases
Chronic Hepatitis
Liver Diseases
Carcinogenesis
Fibrosis
Chronic Disease
Clone Cells
Biopsy

Keywords

  • chronic hepatitis
  • hepatocellular carcinoma
  • liver cirrhosis
  • precancerous condition
  • pyrosequencing

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage. / Nagashio, Ryo; Arai, Eri; Ojima, Hidenori; Kosuge, Tomoo; Kondo, Yutaka; Kanai, Yae.

In: International Journal of Cancer, Vol. 129, No. 5, 01.09.2011, p. 1170-1179.

Research output: Contribution to journalArticle

@article{c8dc9f557ce14d1599004c0f45699d03,
title = "Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage",
abstract = "For appropriate surveillance of patients at the precancerous stage for hepatocellular carcinomas (HCCs), carcinogenetic risk estimation is advantageous. The aim of our study was to establish criteria for such estimation based on DNA methylation profiling. The DNA methylation status of 203 CpG sites on 25 bacterial artificial chromosome (BAC) clones, whose DNA methylation status had been proven to discriminate samples of noncancerous liver tissue obtained from patients with HCC (N) from normal liver tissue (C) samples by BAC array-based methylated CpG island amplification, was evaluated quantitatively using pyrosequencing. The 45 CpG sites whose DNA methylation levels differed significantly between C and N in the learning cohort (n = 22) were identified. The criteria combining DNA methylation status for the 30 regions including the 45 CpG sites were able to diagnose N as being at high risk of carcinogenesis with 100{\%} sensitivity and specificity in the learning cohort and 95.6{\%} sensitivity and 100{\%} specificity in the validation (n = 90) cohort. DNA methylation status for the 30 regions in N samples was significantly correlated with the outcome of patients with HCCs, indicating that clinicopathologically valid DNA methylation alterations have already accumulated at the precancerous stage. The DNA methylation status of the 30 regions did not depend on the presence or absence of hepatitis virus infection, or the status of noncancerous liver tissue (chronic hepatitis or cirrhosis). These criteria may be applicable for carcinogenetic risk estimation using liver biopsy specimens obtained from patients who are followed up because of chronic liver diseases.",
keywords = "chronic hepatitis, hepatocellular carcinoma, liver cirrhosis, precancerous condition, pyrosequencing",
author = "Ryo Nagashio and Eri Arai and Hidenori Ojima and Tomoo Kosuge and Yutaka Kondo and Yae Kanai",
year = "2011",
month = "9",
day = "1",
doi = "10.1002/ijc.26061",
language = "English",
volume = "129",
pages = "1170--1179",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage

AU - Nagashio, Ryo

AU - Arai, Eri

AU - Ojima, Hidenori

AU - Kosuge, Tomoo

AU - Kondo, Yutaka

AU - Kanai, Yae

PY - 2011/9/1

Y1 - 2011/9/1

N2 - For appropriate surveillance of patients at the precancerous stage for hepatocellular carcinomas (HCCs), carcinogenetic risk estimation is advantageous. The aim of our study was to establish criteria for such estimation based on DNA methylation profiling. The DNA methylation status of 203 CpG sites on 25 bacterial artificial chromosome (BAC) clones, whose DNA methylation status had been proven to discriminate samples of noncancerous liver tissue obtained from patients with HCC (N) from normal liver tissue (C) samples by BAC array-based methylated CpG island amplification, was evaluated quantitatively using pyrosequencing. The 45 CpG sites whose DNA methylation levels differed significantly between C and N in the learning cohort (n = 22) were identified. The criteria combining DNA methylation status for the 30 regions including the 45 CpG sites were able to diagnose N as being at high risk of carcinogenesis with 100% sensitivity and specificity in the learning cohort and 95.6% sensitivity and 100% specificity in the validation (n = 90) cohort. DNA methylation status for the 30 regions in N samples was significantly correlated with the outcome of patients with HCCs, indicating that clinicopathologically valid DNA methylation alterations have already accumulated at the precancerous stage. The DNA methylation status of the 30 regions did not depend on the presence or absence of hepatitis virus infection, or the status of noncancerous liver tissue (chronic hepatitis or cirrhosis). These criteria may be applicable for carcinogenetic risk estimation using liver biopsy specimens obtained from patients who are followed up because of chronic liver diseases.

AB - For appropriate surveillance of patients at the precancerous stage for hepatocellular carcinomas (HCCs), carcinogenetic risk estimation is advantageous. The aim of our study was to establish criteria for such estimation based on DNA methylation profiling. The DNA methylation status of 203 CpG sites on 25 bacterial artificial chromosome (BAC) clones, whose DNA methylation status had been proven to discriminate samples of noncancerous liver tissue obtained from patients with HCC (N) from normal liver tissue (C) samples by BAC array-based methylated CpG island amplification, was evaluated quantitatively using pyrosequencing. The 45 CpG sites whose DNA methylation levels differed significantly between C and N in the learning cohort (n = 22) were identified. The criteria combining DNA methylation status for the 30 regions including the 45 CpG sites were able to diagnose N as being at high risk of carcinogenesis with 100% sensitivity and specificity in the learning cohort and 95.6% sensitivity and 100% specificity in the validation (n = 90) cohort. DNA methylation status for the 30 regions in N samples was significantly correlated with the outcome of patients with HCCs, indicating that clinicopathologically valid DNA methylation alterations have already accumulated at the precancerous stage. The DNA methylation status of the 30 regions did not depend on the presence or absence of hepatitis virus infection, or the status of noncancerous liver tissue (chronic hepatitis or cirrhosis). These criteria may be applicable for carcinogenetic risk estimation using liver biopsy specimens obtained from patients who are followed up because of chronic liver diseases.

KW - chronic hepatitis

KW - hepatocellular carcinoma

KW - liver cirrhosis

KW - precancerous condition

KW - pyrosequencing

UR - http://www.scopus.com/inward/record.url?scp=79959756667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959756667&partnerID=8YFLogxK

U2 - 10.1002/ijc.26061

DO - 10.1002/ijc.26061

M3 - Article

C2 - 21400512

AN - SCOPUS:79959756667

VL - 129

SP - 1170

EP - 1179

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -